ASX ANNOUNCEMENT 20 September 2017

ESENSE OPENS NEW R&D AND PRODUCTION FACILITY

Life sciences company **eSense-Lab Ltd ("eSense" or the "Company")**, **(ASX: ESE)**, is pleased to announce the opening of its new research and development (R&D) and customer support service facility in Israel, landmarking one of the major expansion goals of the Company for its rapid growth and global positioning within the biotechnology and pharmaceutical industries.

The facility will be used to formulate and analyze new Cannabis profiles, as well as for the development of new products and formulations in, but not limited to, nutraceuticals, food and beverage, cosmetics and E-liquids.

Occupying approximately 500 square meters, the facility is situated at the synergistic 'Daren Labs', an Israeli R&D hub for fast-growing biomedical science, bioengineering, medical technology (MedTech), personal care, food science and nutrition companies.

The facilities' capabilities allow for the development of new products, the development of new applications for existing products, as well as pre-clinical research, and will house the Company's new Gas Chromatography built on a mass spectrometric detection unit (GC-MS). Additionally, the facility is equipped for physical and chemical characterization of materials, the support for nutraceutical clients with prototypes, as well as formulation and process development.

Commenting on the announcement, eSense-Lab's CEO Haim Cohen, said: "We are excited to have now occupied our new facilities, which allows the Company to expand its R&D strategy, whilst also providing for the in-house technology and assets to rapidly encroach on the new market opportunities at hand. Importantly, an additional key benefit is a significant reduction, anticipated to be up to 76%, in our monthly operational expenses through this move.

Ends

About eSense-Lab

eSense-Lab Limited (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense–Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost.

To learn more about eSense – Lab, visit www.esense-lab.com

All enquires please contact:

Corporate Advisors
Otsana Capital
108 Outram Street
West Perth WA 6005
Telephone: +61 8 9486 7244
www.otsana.com